BACKGROUND: To test the effect of race/ethnicity on cancer-specific mortality (CSM) after salvage radical prostatectomy (SRP). MATERIAL AND METHODS: We relied on the Surveillance, Epidemiology and End Results database (SEER, 2004-2016) to identify SRP patients of all race/ethnicity background. Univariate and multivariate Cox regression models addressed CSM according to race/ethnicity. RESULTS: Of 426 assessable SRP patients, Caucasians accounted for 299 (69.9%) vs. 68 (15.9%) African-Americans vs. 39 (9.1%) Hispanics vs. 20 (4.7%) Asians. At diagnosis, African-Americans (64 years) were younger than Caucasians (66 years), but not younger than Hispanics (66 years) and Asians (67 years). PSA at diagnosis was significantly higher in African-Americans (13.2 ng/ml), Hispanics (13.0 ng/ml), and Asians (12.2 ng/ml) than in Caucasians (7.8 ng/ml, p = 0.01). Moreover, the distribution of African-Americans (10.3%-36.6%) and Hispanics (0%-15.8%) varied according to SEER region. The 10-year CSM was 46.5% in African-Americans vs. 22.4% in Caucasians vs. 15.4% in Hispanics vs. 15.0% in Asians. After multivariate adjustment (for age, clinical T stage, lymph node dissection status), African-American race/ethnicity was an independent predictor of higher CSM (HR: 2.2, p < 0.01), but not Hispanic or Asian race/ethnicity. The independent effect of African-American race/ethnicity did not persist after further adjustment for PSA. CONCLUSION: African-Americans treated with SRP are at higher risk of CSM than other racial/ethnic groups and also exhibited the highest baseline PSA. The independent effect of African-American race/ethnicity on higher CSM no longer applies after PSA adjustment since higher PSA represents a distinguishing feature in African-American patients.

Cancer Prognostics and Health Outcomes Unit Division of Urology University of Montréal Health Center Montréal QC Canada

Department of Neurosciences Reproductive Sciences and Odontostomatology University of Naples Federico 2 Naples Italy

Department of Urology 2nd Faculty of Medicine Charles University Prag Czechia

Department of Urology and Division of Experimental Oncology URI Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University Hospital Frankfurt Goethe University Frankfurt Frankfurt Germany

Department of Urology University of Texas Southwestern Dallas TX United States

Departments of Urology Weill Cornell Medical College New York NY United States

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany

Zobrazit více v PubMed

Mottet N, Cornford P, Van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. . EAU - EANM - ESTRO - ESUR - SIOG. guidelines on prostate cancer. Eur Urol (2020). PubMed

Mohler JL, Srinvicas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. . Prostate cancer, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw (2020).

Schmid M, Meyer CP, Reznor G, Choueiri TK, Hanske J, Sammon JD, et al. . Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol (2016) 2(1):85–93. doi: 10.1001/jamaoncol.2015.3384 PubMed DOI PMC

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, et al. . Trends in disparate treatment of African American men with localized prostate cancer across national comprehensive cancer network risk groups. Urology (2014) 84(2):386–92. doi: 10.1016/j.urology.2014.05.009 PubMed DOI

Würnschimmel C, Nocera L, Wenzel M, Ruvolo CC, Tian Z, Saad F, et al. . Race/Ethnicity may be an important predictor of life expectancy in localized prostate cancer patients: Novel analyses using social security administration life tables. J Racial Ethn Health Disparities (2022). doi: 10.1007/s40615-022-01257-y PubMed DOI PMC

Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Tian Z, Saad F, et al. . External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. Int J Urol (2022) 29(1):17–24. doi: 10.1111/iju.14701 PubMed DOI

Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, et al. . Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis (2019) 22(1):125–36. doi: 10.1038/s41391-018-0083-4 PubMed DOI

Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, et al. . Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. Int J Urol (2021) 28(8):862–9. doi: 10.1111/iju.14595 PubMed DOI

Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, et al. . The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urol Oncol (2021) 39(11):785.e11–785.e17. doi: 10.1016/j.urolonc.2021.04.004 PubMed DOI

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. . Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol (2019) 5(7):975–83. doi: 10.1001/jamaoncol.2019.0826 PubMed DOI PMC

Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, et al. . Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. World J Urol (2021) 39(10):3781–7. doi: 10.1007/s00345-021-03720-7 PubMed DOI PMC

About the SEER program. SEER. Available at: https://seer.cancer.gov/about/overview.html.

Pokala N, Huynh DL, Henderson AA, Johans C. Survival outcomes in men undergoing radical prostatectomy after primary radiation treatment for adenocarcinoma of the prostate. Clin Genitourin Cancer (2016) 14(3):218–25. doi: 10.1016/j.clgc.2015.12.010 PubMed DOI

RCT . R: A language and environment for statistical computing (2017). Available at: https://wwwr-projectorg2017.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, et al. . Racial disparities in lymph node dissection at radical prostatectomy: A surveillance, epidemiology and end results database analysis. Int J Urol (2018) 25(11):929–36. doi: 10.1111/iju.13780 PubMed DOI

Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, et al. . Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy. Urol Oncol (2016) 34(1):3.e9–14. doi: 10.1016/j.urolonc.2015.08.004 PubMed DOI

Amini E, Palmer TC, Cai J, Lieskovsky G, Daneshmand S, Djaladat H. Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study. World J Urol (2018) 36(8):1233–9. doi: 10.1007/s00345-018-2266-y PubMed DOI

Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol (1995) 13(1):93–100. doi: 10.1200/JCO.1995.13.1.93 PubMed DOI

Kamel MH, Bimali M, Khalil MI, Eltahawy E, Su LJ, Bissada NK, et al. . Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among caucasians and African americans treated by surgery or radiation. Int Urol Nephrol (2019) 51(4):561–9. doi: 10.1007/s11255-019-02116-2 PubMed DOI

Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, Shariat SF, et al. . Racial/Ethnic disparities in tumor characteristics and treatments in favorable and unfavorable intermediate risk prostate cancer. J Urol (2021) 206(1):69–79. doi: 10.1097/JU.0000000000001695 PubMed DOI

Wenzel M, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, Shariat SF, et al. . Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across united states SEER registries. Cancer Epidemiol (2021) 74:101994. doi: 10.1016/j.canep.2021.101994 PubMed DOI

Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, et al. . The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. World J Urol (2022) 40(1):103–10. doi: 10.1007/s00345-021-03816-0 PubMed DOI

Velasquez MC, Chinea FM, Kwon D, Prakash NS, Barboza MP, Gonzalgo ML, et al. . The influence of ethnic heterogeneity on prostate cancer mortality after radical prostatectomy in Hispanic or Latino men: A population-based analysis. Urology (2018) 117:108–14. doi: 10.1016/j.urology.2018.03.036 PubMed DOI PMC

Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, et al. . Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev (2013) 22(5):891–7. doi: 10.1158/1055-9965.EPI-12-1238 PubMed DOI PMC

Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, et al. . African American Men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 31(24):2991–7. doi: 10.1200/JCO.2012.47.0302 PubMed DOI PMC

Heidenreich A, Ohlmann C, Ozgür E, Engelmann U. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy]. Urologe A (2006) 45(4):474–81. doi: 10.1007/s00120-006-0995-9 PubMed DOI

Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. . Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 60(2):205–10. doi: 10.1016/j.eururo.2011.03.011 PubMed DOI PMC

Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, et al. . Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 176(5):2025–31. doi: 10.1016/j.juro.2006.07.075 PubMed DOI

Mandel P, Steuber T, Ahyai S, Kriegmair M, Schiffmann J, Boehm K, et al. . Salvage radical prostatectomy for recurrent prostate cancer: verification of European association of urology guideline criteria. BJU Int (2016) 117(1):55–61. doi: 10.1111/bju.13103 PubMed DOI

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, et al. . The effect of other-cause mortality adjustment on access to alternative treatment modalities for localized prostate cancer among African American patients. Eur Urol Oncol (2018) 1(3):215–22. doi: 10.1016/j.euo.2018.03.007 PubMed DOI

Preisser F, Würnschimmel C, Pose RM, Heinze A, Steuber T, Michl U, et al. . Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer. Prostate (2022) 82(2):254–9. doi: 10.1002/pros.24268 PubMed DOI

Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, et al. . Salvage radical prostatectomy: Baseline prostate cancer characteristics and survival across SEER registries. Clin Genitourin Cancer (2021) 19(4):e255–63. doi: 10.1016/j.clgc.2021.03.015 PubMed DOI

Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, et al. . The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. Prostate (2021) 81(6):339–46. doi: 10.1002/pros.24112 PubMed DOI

Noone A-M, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. . Comparison of SEER treatment data with Medicare claims. Med Care (2016) 54(9):e55–64. doi: 10.1097/MLR.0000000000000073 PubMed DOI PMC

Leonardo C, Simone G, Papalia R, Franco G, Guaglianone S, Gallucci M. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. Int J Urol (2009) 16(6):584–6. doi: 10.1111/j.1442-2042.2008.02209.x PubMed DOI

Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol (2010) 57(3):437–43. doi: 10.1016/j.eururo.2009.02.041 PubMed DOI